KLK3 and prostate carcinoma: The U.S. Food and Drug Administration approved trans-1-amino-3-18f-flucyclobutane carboxylic acid (anti-[18F]-FACBC) PET to detect prostate cancer in patients with elevated prostate-specific antigen after treatment in 2016 [68].